论文部分内容阅读
目的比较前列地尔不同给药时间治疗高龄糖尿病并慢性肾脏病的疗效。方法选择2014年1月—2015年1于白城市解放军321医院住院的高龄糖尿病合并慢性肾脏病患者70例,随机分为Ⅰ组和Ⅱ组,各35例。Ⅰ组予以10μg前列地尔注射液静脉推注+基础治疗,1次/d,持续14d,洗脱14d后予以基础治疗持续14d;Ⅱ组先予以基础治疗14d,再予以10μg前列地尔注射液静脉推注+基础治疗,1次/d,持续14d;观察两组肾功能及尿蛋白的主要观察指标、凝血功能、血糖等次要观察指标、不良反应。结果治疗前两组患者观察指标比较,差异无统计学意义(P>0.05),治疗后两组患者观察指标比较,差异有统计学意义(P<0.05),治疗后尿清蛋白排泄率(UAER)、ACR、总胆固醇(CHOL)、低密度脂蛋白胆固醇(LDL-C)均低于治疗前,差异有统计学意义(P<0.05)。两组患者在治疗期间均未发生严重不良反应。结论基础治疗后给予前列地尔治疗高龄糖尿病并慢性肾脏病的疗效确切,安全性高。
Objective To compare the therapeutic effects of alprostadil with different administration time on the treatment of advanced diabetes and chronic kidney disease. Methods From January 2014 to January 2015, 70 elderly patients with diabetes mellitus and chronic kidney disease hospitalized in PLA 321 Hospital of Baicheng City were randomly divided into group Ⅰ and group Ⅱ (n = 35). Group Ⅰ was given 10μg alprostadil intravenous injection + basic therapy, 1 time / d for 14 days, after 14 days of elution, basic treatment was continued for 14 days. Group Ⅱ was given basic treatment for 14 days, then 10μg alprostadil injection Intravenous bolus + basic treatment, 1 time / d, continued for 14 days; observed renal function and urine protein of the two main observation indicators, coagulation, blood glucose and other secondary indicators of adverse reactions. Results Before treatment, there was no significant difference between the two groups (P> 0.05). After treatment, there was significant difference between the two groups (P <0.05). After treatment, the urinary albumin excretion rate (UAER ), ACR, total cholesterol (CHOL), low density lipoprotein cholesterol (LDL-C) were lower than before treatment, the difference was statistically significant (P <0.05). Two groups of patients during the treatment did not occur serious adverse reactions. Conclusion The treatment of Alzheimer’s with advanced diabetes mellitus and chronic kidney disease after the basic treatment is effective and safe.